Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
MGC026 is an investigational, clinical ADC incorporating a B7-H3-targeting antibody and a novel topoisomerase I inhibitor-based linker-payload, SYNtecan E™. This cleavable linker payload is based on exatecan, a clinically-validated and potent camptothecin that readily combines with Synaffix’s HydraSpace™ technology.
We believe Synaffix’s approach potentially provides advantages vis-à-vis other topoisomerase I inhibitor-based ADCs. In fact, Exatecan appears to be more potent and less susceptible to multi-drug resistance (MDR) mechanisms than other TOP1 inhibitors, such as SN38 and deruxtecan. Additionally, site-specific conjugation of SYNtecan to the normally glycosylated amino acid in the Fc domain abolishes FcGamma receptor and mannose receptor binding, which contribute to non-targeted uptake of ADCs in alveolar macrophages and reported to be associated with lung toxicity, and therefore may provide a safety benefit for patients.
Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on MGC026.
Our Rights
MacroGenics retains global rights to MGC026.
Clinical Trials
Presentations & Publications
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.